2007
DOI: 10.1111/j.1537-2995.2007.01196.x
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the COM.TEC cell separator in predicting the yield of harvested CD34+ cells

Abstract: The significantly better collection efficiency of CD34+ cells and the more exact prediction of the harvested CD34+ cell yield make the leukapheresis program MNC a safe and efficient procedure. However, concentrates collected by RV-PBSC are of a better cellular quality with a significantly higher percentage of mononuclear and CD34+ cells and a lower contamination by erythrocytes and platelets.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
8
0

Year Published

2009
2009
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(8 citation statements)
references
References 44 publications
(94 reference statements)
0
8
0
Order By: Relevance
“…The autoMNC program is an established program that has been shown to result in higher CE and better prediction of the CD34+ yield. [ 17 18 ]…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…The autoMNC program is an established program that has been shown to result in higher CE and better prediction of the CD34+ yield. [ 17 18 ]…”
Section: Methodsmentioning
confidence: 99%
“…Collection efficiency, a percentage measure of the cell separator's ability to extract maximum number of CD34+ cells from the cells available in the donor's blood was calculated as follows[ 15 16 17 18 19 ]:…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The auto mononuclear cell (MNC) collection program of the COM.TEC cell separator (Fresenius HemoCare GmbH, Bad Homburg, Germany) was recently introduced for the collection of PBPCs in patients and allogeneic donors. There have been several reports regarding collection variables and contents of the harvest with the COM.TEC cell separator 4‐6 and its comparative performance with other cell separators 7 . However, there have been no reports on the performance and clinical feasibility of the instrument for the collection of PBPC in pediatric groups.…”
mentioning
confidence: 99%
“…The amount of CD34 1 cells mobilized greatly varies patient wise, depending on: diagnoses, previous chemotherapy and, probably, other poorly known factors [11,17,18]. The yield of CD34 1 cells per apheresis depends on mobilizing agents and other factors, the most important are: the number of previous chemotherapy cycles, the time elapsed between the last chemotherapy and the apheresis procedure, and the amount of PBPCs at the beginning of the apheresis [19][20][21][22][23].…”
Section: Introductionmentioning
confidence: 99%